Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Becton Dickinson ( (BDX) ).
On February 10, 2026, BD launched a series of cash tender offers for up to $1.6 billion in aggregate purchase price of 15 tranches of outstanding senior notes and debentures, ranging in maturity from 2026 to 2050. The offers apply prioritized acceptance levels and series-specific caps, including notable sub-caps on certain long-dated notes, and provide early tender incentives for holders who participate by February 24, ahead of a March 11 expiration.
By targeting a broad mix of near-, medium- and long-dated securities, the transaction is designed to actively manage BD’s debt profile and could lower interest costs and extend or rebalance its maturity schedule. The move underscores the company’s continued focus on balance sheet optimization, with potential implications for its credit metrics and flexibility to invest in core medical technology operations, while offering bondholders an opportunity to exit positions at defined pricing spreads over U.S. Treasuries.
The most recent analyst rating on (BDX) stock is a Buy with a $202.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.
Spark’s Take on BDX Stock
According to Spark, TipRanks’ AI Analyst, BDX is a Neutral.
BDX scores in the mid-range driven by stable operating fundamentals and a constructive price trend, but held back by softer recent cash-flow trends and meaningful leverage. An elevated P/E is an additional constraint, while earnings-call commentary supports stability (cost-out execution and capital return) but flags notable near-term headwinds from tariffs, China dynamics, and Alaris remediation.
To see Spark’s full report on BDX stock, click here.
More about Becton Dickinson
Becton, Dickinson and Company (BD) is a leading global medical technology company that develops, manufactures and sells devices, instrument systems and reagents for healthcare institutions, life science researchers, clinical laboratories and the pharmaceutical industry. The company focuses on improving drug delivery, diagnostics and care delivery, with a significant presence in U.S. and international healthcare markets.
Average Trading Volume: 2,075,962
Technical Sentiment Signal: Buy
Current Market Cap: $59.84B
For a thorough assessment of BDX stock, go to TipRanks’ Stock Analysis page.